{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T17:02:29Z","timestamp":1784998949765,"version":"3.55.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T00:00:00Z","timestamp":1781308800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T00:00:00Z","timestamp":1781308800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Platinum-resistant ovarian cancer (PROC) remains a major clinical challenge due to limited therapeutic options and poor prognosis. Conventional treatments provide only modest benefits, and immune checkpoint inhibitors have shown limited efficacy in unselected populations, underscoring the need for biomarker-driven strategies. Mirvetuximab soravtansine (MIRV) is a first-in-class antibody\u2013drug conjugate targeting folate receptor alpha (FR\u03b1), which is highly expressed in a substantial proportion of epithelial ovarian cancers. By combining selective tumor targeting with intracellular delivery of the cytotoxic payload DM4, MIRV achieves potent antitumor activity with a manageable safety profile and evidence of a clinically relevant bystander effect. Clinical trials including SORAYA and MIRASOL demonstrated that MIRV significantly improved response rates, progression-free survival, and overall survival in patients with FR\u03b1-high PROC, thereby establishing MIRV as a clinically meaningful treatment option. Ongoing research is evaluating MIRV by using combination regimens, earlier treatment lines, and maintenance strategies. Despite these advances, challenges remain, including resistance mechanisms, optimization of biomarker assessments, and cost considerations. Future efforts should focus on refined patient selection, rational combination strategies, and next-generation antibody\u2013drug conjugates, which are expected to further expand the clinical utility of FR\u03b1-targeted therapy.<\/jats:p>","DOI":"10.1007\/s10147-026-03090-3","type":"journal-article","created":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T12:51:17Z","timestamp":1781355077000},"page":"1527-1537","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Mirvetuximab soravtansine in platinum-resistant ovarian cancer: from biological rationale to clinical impact and future directions"],"prefix":"10.1007","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1803-1166","authenticated-orcid":false,"given":"Seiji","family":"Mabuchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ai","family":"Kusakabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyuki","family":"Sasano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,13]]},"reference":[{"key":"3090_CR1","doi-asserted-by":"publisher","first-page":"1258228","DOI":"10.3389\/fonc.2023.1258228","volume":"13","author":"RN Eskander","year":"2023","unstructured":"Eskander RN, Moore KN, Monk BJ et al (2023) Overcoming the challenges of drug development in platinum-resistant ovarian cancer. Front Oncol 13:1258228. https:\/\/doi.org\/10.3389\/fonc.2023.1258228","journal-title":"Front Oncol"},{"key":"3090_CR2","doi-asserted-by":"publisher","first-page":"e473114","DOI":"10.1200\/EDBK-25-473114","volume":"45","author":"KN Moore","year":"2025","unstructured":"Moore KN, Liu JF, Lorusso D (2025) State of the art: therapies now and around the corner for gynecologic cancers. Am Soc Clin Oncol Educ Book 45:e473114. https:\/\/doi.org\/10.1200\/EDBK-25-473114","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"3090_CR3","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1111\/jog.13947","volume":"45","author":"N Komura","year":"2019","unstructured":"Komura N, Mabuchi S, Isohashi F et al (2019) Radiotherapy for isolated recurrent epithelial ovarian cancer: a single institutional experience. J Obstet Gynaecol Res 45:1173\u20131182","journal-title":"J Obstet Gynaecol Res"},{"key":"3090_CR4","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1002\/jso.21652","volume":"102","author":"J Sehouli","year":"2010","unstructured":"Sehouli J, Richter R, Braicu EI et al (2010) Role of secondary cytoreductive surgery in ovarian cancer relapse: who will benefit? J Surg Oncol 102:656\u2013662","journal-title":"J Surg Oncol"},{"key":"3090_CR5","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/nrd.2016.268","volume":"16","author":"A Beck","year":"2017","unstructured":"Beck A, Goetsch L, Dumontet C et al (2017) Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov 16:315\u2013337","journal-title":"Nat Rev Drug Discov"},{"key":"3090_CR6","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/j.ygyno.2007.11.020","volume":"108","author":"KR Kalli","year":"2008","unstructured":"Kalli KR, Oberg AL, Keeney GL et al (2008) Folate receptor alpha as a tumor target in epithelial ovarian cancer. Gynecol Oncol 108:619\u2013626","journal-title":"Gynecol Oncol"},{"key":"3090_CR7","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1038\/bjc.2014.567","volume":"111","author":"M K\u00f6bel","year":"2014","unstructured":"K\u00f6bel M, Madore J, Ramus SJ et al (2014) Evidence for a time-dependent association between FOLR1 expression and survival from ovarian carcinoma: implications for clinical testing. An Ovarian Tumour Tissue Analysis consortium study. Br J Cancer 111:2297\u20132307","journal-title":"Br J Cancer"},{"key":"3090_CR8","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.ygyno.2017.08.015","volume":"147","author":"LP Martin","year":"2017","unstructured":"Martin LP, Konner JA, Moore KN et al (2017) Characterization of folate receptor alpha (FR\u03b1) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: A phase I expansion study of the FR\u03b1-targeting antibody-drug conjugate mirvetuximab soravtansine. Gynecol Oncol 147:402\u2013407","journal-title":"Gynecol Oncol"},{"key":"3090_CR9","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1038\/s41416-022-02031-x","volume":"128","author":"HJ Bax","year":"2023","unstructured":"Bax HJ, Chauhan J, Stavraka C et al (2023) Folate receptor alpha in ovarian cancer tissue and patient serum is associated with disease burden and treatment outcomes. Br J Cancer 128:342\u2013353","journal-title":"Br J Cancer"},{"key":"3090_CR10","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1158\/1535-7163.MCT-14-1095","volume":"14","author":"O Ab","year":"2015","unstructured":"Ab O, Whiteman KR, Bartle LM et al (2015) IMGN853, a folate receptor alpha-targeting antibody-drug conjugate, exhibits potent targeted antitumor activity against folate receptor alpha-expressing tumors. Mol Cancer Ther 14:1605\u20131613","journal-title":"Mol Cancer Ther"},{"key":"3090_CR11","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1200\/JCO.2016.69.9538","volume":"35","author":"KN Moore","year":"2017","unstructured":"Moore KN, Martin LP, O\u2019Malley DM et al (2017) Safety and activity of mirvetuximab soravtansine in platinum-resistant ovarian cancer: a phase I study. J Clin Oncol 35:1112\u20131118","journal-title":"J Clin Oncol"},{"key":"3090_CR12","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.annonc.2021.02.017","volume":"32","author":"KN Moore","year":"2021","unstructured":"Moore KN, Oza AM, Colombo N et al (2021) Phase III randomized trial of mirvetuximab soravtansine versus chemotherapy in platinum-resistant ovarian cancer. Ann Oncol 32:757\u2013765","journal-title":"Ann Oncol"},{"key":"3090_CR13","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1200\/JCO.22.01900","volume":"41","author":"UA Matulonis","year":"2023","unstructured":"Matulonis UA, Lorusso D, Oaknin A et al (2023) Efficacy and safety of mirvetuximab soravtansine in patients with platinum-resistant ovarian cancer with high folate receptor alpha expression: results from the SORAYA study. J Clin Oncol 41:2436\u20132445","journal-title":"J Clin Oncol"},{"key":"3090_CR14","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1056\/NEJMoa2309169","volume":"389","author":"KN Moore","year":"2023","unstructured":"Moore KN, Angelergues A, Konecny GE et al (2023) Mirvetuximab soravtansine in FR\u03b1-positive platinum-resistant ovarian cancer. N Engl J Med 389:2162\u20132174","journal-title":"N Engl J Med"},{"key":"3090_CR15","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1136\/ijgc-2024-005401","volume":"34","author":"RL Coleman","year":"2024","unstructured":"Coleman RL, Lorusso D, Oaknin A et al (2024) Mirvetuximab soravtansine in folate receptor alpha (FR\u03b1)-high platinum-resistant ovarian cancer: final overall survival and post hoc sequence of therapy subgroup results from the SORAYA trial. Int J Gynecol Cancer 34:1119\u20131125","journal-title":"Int J Gynecol Cancer"},{"key":"3090_CR16","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.ygyno.2023.07.010","volume":"176","author":"A Saito","year":"2023","unstructured":"Saito A, Nishikawa T, Yoshida H et al (2023) Folate receptor alpha is widely expressed and a potential therapeutic target in uterine and ovarian carcinosarcoma. Gynecol Oncol 176:115\u2013121","journal-title":"Gynecol Oncol"},{"key":"3090_CR17","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.molonc.2011.11.010","volume":"6","author":"YL Chen","year":"2012","unstructured":"Chen YL, Chang MC, Huang CY et al (2012) Serous ovarian carcinoma patients with high alpha-folate receptor had reducing survival and cytotoxic chemo-response. Mol Oncol 6:360\u2013369","journal-title":"Mol Oncol"},{"key":"3090_CR18","doi-asserted-by":"publisher","first-page":"191","DOI":"10.3390\/cancers14010191","volume":"14","author":"A Wallace-Povirk","year":"2021","unstructured":"Wallace-Povirk A, Hou Z, Nayeen MJ et al (2021) Folate transport and one-carbon metabolism in targeted therapies of epithelial ovarian cancer. Cancers (Basel) 14:191. https:\/\/doi.org\/10.3390\/cancers14010191","journal-title":"Cancers (Basel)"},{"key":"3090_CR19","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1002\/ijc.21712","volume":"119","author":"LE Kelemen","year":"2006","unstructured":"Kelemen LE (2006) The role of folate receptor alpha in cancer development, progression and treatment: cause, consequence or innocent bystander? Int J Cancer 119:243\u2013250","journal-title":"Int J Cancer"},{"key":"3090_CR20","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1097\/PGP.0b013e3182774562","volume":"32","author":"DJ O'Shannessy","year":"2013","unstructured":"O\u2019Shannessy DJ, Somers EB, Smale R et al (2013) Expression of folate receptor-\u03b1 (FRA) in gynecologic malignancies and its relationship to the tumor type. Int J Gynecol Pathol 32:258\u2013268","journal-title":"Int J Gynecol Pathol"},{"key":"3090_CR21","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s13402-011-0052-6","volume":"35","author":"LM Crane","year":"2012","unstructured":"Crane LM, Arts HJ, van Oosten M et al (2012) The effect of chemotherapy on expression of folate receptor-alpha in ovarian cancer. Cell Oncol (Dordr) 35:9\u201318","journal-title":"Cell Oncol (Dordr)"},{"key":"3090_CR22","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.ygyno.2013.03.024","volume":"130","author":"E Despierre","year":"2013","unstructured":"Despierre E, Lambrechts S, Leunen K et al (2013) Folate receptor alpha (FRA) expression remains unchanged in epithelial ovarian and endometrial cancer after chemotherapy. Gynecol Oncol 130:192\u2013199","journal-title":"Gynecol Oncol"},{"key":"3090_CR23","doi-asserted-by":"publisher","first-page":"e47201","DOI":"10.1371\/journal.pone.0047201","volume":"7","author":"MK Siu","year":"2012","unstructured":"Liang B, Tenney TB, Han L et al (2026) Heterogeneity and scoring reproducibility of folate receptor 1 immunohistochemistry in high-grade serous carcinoma. Int J Gynecol Pathol 45:9\u201317","journal-title":"PLoS ONE"},{"key":"3090_CR24","doi-asserted-by":"publisher","first-page":"5288","DOI":"10.1158\/1078-0432.CCR-10-0700","volume":"16","author":"JA Konner","year":"2010","unstructured":"Siu MK, Kong DS, Chan HY et al (2012) Paradoxical impact of two folate receptors, FR\u03b1 and RFC, in ovarian cancer: effect on cell proliferation, invasion and clinical outcome. PLoS ONE 7:e47201. https:\/\/doi.org\/10.1371\/journal.pone.0047201","journal-title":"Clin Cancer Res"},{"key":"3090_CR25","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.ygyno.2013.03.002","volume":"129","author":"DK Armstrong","year":"2013","unstructured":"Konner JA, Bell-McGuinn KM, Sabbatini P et al (2010) Farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer: a phase I study. Clin Cancer Res 16:5288\u20135295","journal-title":"Gynecol Oncol"},{"key":"3090_CR26","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/s41571-020-0339-5","volume":"17","author":"M Scaranti","year":"2020","unstructured":"Armstrong DK, White AJ, Weil SC et al (2013) Farletuzumab, a monoclonal antibody against folate receptor alpha, in relapsed platinum-sensitive ovarian cancer. Gynecol Oncol 129:452\u2013458","journal-title":"Nat Rev Clin Oncol"},{"key":"3090_CR27","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/j.neo.2016.11.002","volume":"18","author":"JF Ponte","year":"2016","unstructured":"Scaranti M, Cojocaru E, Banerjee S et al (2020) Exploiting the folate receptor \u03b1 in oncology. Nat Rev Clin Oncol 17:349\u20133594","journal-title":"Neoplasia"},{"key":"3090_CR28","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.ygyno.2020.01.037","volume":"157","author":"DM O'Malley","year":"2020","unstructured":"Kucerova L, Fekiacova A, Udvorkova N et al (2025) Mirvetuximab soravtansine induces potent cytotoxicity and bystander effect in cisplatin-resistant germ cell tumor cells. Cells 14:287. https:\/\/doi.org\/10.3390\/cells14040287","journal-title":"Gynecol Oncol"},{"key":"3090_CR29","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.ygyno.2023.01.020","volume":"170","author":"L Gilbert","year":"2023","unstructured":"Ponte JF, Ab O, Lanieri L et al (2016) Mirvetuximab soravtansine (IMGN853), a folate receptor alpha-targeting antibody-drug conjugate, potentiates the activity of standard of care therapeutics in ovarian cancer models. Neoplasia 18:775\u201378","journal-title":"Gynecol Oncol"},{"key":"3090_CR30","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1097\/PGP.0000000000001140","volume":"45","author":"B Liang","year":"2026","unstructured":"Gilbert L, Oaknin A, Matulonis UA et al (2023) Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FR\u03b1)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer. Gynecol Oncol 170:241\u2013247","journal-title":"Int J Gynecol Pathol"},{"key":"3090_CR31","doi-asserted-by":"publisher","first-page":"287","DOI":"10.3390\/cells14040287","volume":"14","author":"L Kucerova","year":"2025","unstructured":"Tu YP, Hanze E, Zhu F et al (2024) Population pharmacokinetics of mirvetuximab soravtansine in patients with folate receptor-\u03b1 positive ovarian cancer: the antibody-drug conjugate, payload and metabolite. Br J Clin Pharmacol 90:568\u2013581","journal-title":"Cells"},{"key":"3090_CR32","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1111\/bcp.15937","volume":"90","author":"YP Tu","year":"2024","unstructured":"Wang Y, Liu L, Jin X et al (2024) Efficacy and safety of mirvetuximab soravtansine in recurrent ovarian cancer with FR\u03b1 positive expression: a systematic review and meta-analysis. Crit Rev Oncol Hematol 194:104230. https:\/\/doi.org\/10.1016\/j.critrevonc.2023.104230","journal-title":"Br J Clin Pharmacol"},{"key":"3090_CR33","doi-asserted-by":"publisher","first-page":"104230","DOI":"10.1016\/j.critrevonc.2023.104230","volume":"194","author":"Y Wang","year":"2024","unstructured":"Hendershot A, Slabaugh M, Riaz KM et al (2023) Prevention and management of ocular events. Gynecol Oncol Rep 47:101155. https:\/\/doi.org\/10.1016\/j.gore.2023.101155","journal-title":"Crit Rev Oncol Hematol"},{"key":"3090_CR34","doi-asserted-by":"publisher","first-page":"101155","DOI":"10.1016\/j.gore.2023.101155","volume":"47","author":"A Hendershot","year":"2023","unstructured":"Eaton JS, Miller PE, Mannis MJ et al (2015) Ocular adverse events associated with antibody-drug conjugates in human clinical trials. J Ocul Pharmacol Ther 31:589\u2013604","journal-title":"Gynecol Oncol Rep"},{"key":"3090_CR35","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1089\/jop.2015.0064","volume":"31","author":"JS Eaton","year":"2015","unstructured":"Peng J, Tetali A, Malik A et al (2025) Comprehensive review of the ocular toxicities associated with antibody-drug conjugates used to treat gynecological cancers. Cureus 17:e87453. https:\/\/doi.org\/10.7759\/cureus.87453","journal-title":"J Ocul Pharmacol Ther"},{"key":"3090_CR36","doi-asserted-by":"publisher","first-page":"e87453","DOI":"10.7759\/cureus.87453","volume":"17","author":"J Peng","year":"2025","unstructured":"Elahere (mirvetuximab soravtansine-gynx) prescribing information. U.S. Food and Drug Administration. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/761310Origs005lbl.pdf Accessed 18 May 2026","journal-title":"Cureus"},{"key":"3090_CR37","doi-asserted-by":"crossref","unstructured":"Van Gorp T, Moore KN, Konecny GE et al (2025) Patient-reported outcomes from the MIRASOL trial evaluating mirvetuximab soravtansine versus chemotherapy in patients with folate receptor \u03b1-positive, platinum-resistant ovarian cancer: a randomised, open-label, phase 3 trial. Lancet Oncol 26:503\u2013515","DOI":"10.1016\/S1470-2045(25)00021-X"},{"key":"3090_CR38","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/S1470-2045(25)00021-X","volume":"26","author":"T Van Gorp","year":"2025","unstructured":"O\u2019Malley DM, Matulonis UA, Birrer MJ et al (2020) Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FR\u03b1)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer. Gynecol Oncol 157:379\u2013385","journal-title":"Lancet Oncol"},{"key":"3090_CR39","unstructured":"ClinicalTrials.gov. U.S. National Library of Medicine. Available at: https:\/\/clinicaltrials.gov\/. Accessed 18 May 2026"},{"key":"3090_CR40","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.ygyno.2024.01.045","volume":"185","author":"DL Richardson","year":"2024","unstructured":"Richardson DL, Moore KN, Vergote I et al (2024) Phase 1b study of mirvetuximab soravtansine, a folate receptor alpha (FR\u03b1)-targeting antibody-drug conjugate, in combination with carboplatin and bevacizumab in patients with platinum-sensitive ovarian cancer. Gynecol Oncol 185:186\u2013193","journal-title":"Gynecol Oncol"},{"key":"3090_CR41","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1080\/14796694.2024.2372241","volume":"20","author":"DM O\u2019Malley","year":"2024","unstructured":"O\u2019Malley DM, Myers T, Wimberger P et al (2024) Maintenance with mirvetuximab soravtansine plus bevacizumab. Future Oncol 20:2423\u20132436","journal-title":"Future Oncol"},{"key":"3090_CR42","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.5858\/arpa.2023-0149-OA","volume":"148","author":"RL James","year":"2024","unstructured":"James RL, Sisserson T, Cai Z et al (2024) Development of an FR\u03b1 companion diagnostic immunohistochemical assay for mirvetuximab soravtansine. Arch Pathol Lab Med 148:1226\u20131233","journal-title":"Arch Pathol Lab Med"},{"key":"3090_CR43","doi-asserted-by":"publisher","first-page":"e71","DOI":"10.3802\/jgo.2024.35.e71","volume":"35","author":"Y Zhu","year":"2024","unstructured":"Zhu Y, Lin Y, Liu K et al (2024) Mirvetuximab soravtansine in platinum-resistant recurrent ovarian cancer with high folate receptor-alpha expression: a cost-effectiveness analysis. J Gynecol Oncol 35:e71. https:\/\/doi.org\/10.3802\/jgo.2024.35.e71","journal-title":"J Gynecol Oncol"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-03090-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-026-03090-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-03090-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T16:35:33Z","timestamp":1784997333000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-026-03090-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,13]]},"references-count":43,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["3090"],"URL":"https:\/\/doi.org\/10.1007\/s10147-026-03090-3","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,13]]},"assertion":[{"value":"27 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflicts of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}